Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Inflammatory Response01:28

Inflammatory Response

17.4K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.4K
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

17.3K
The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
17.3K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

950
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
950

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation.

Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V·2026
Same author

Adiponectin modulates the diurnal hepatic transcriptome and energy metabolism in male mice.

Endocrine connections·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026
Same author

Pharmacogenetics-Not Just Low-Hanging Fruit.

Clinical pharmacology and therapeutics·2026
Same author

Response to High-Dose Topical Capsaicin in Neuropathic Pain: Absence of Deep Pain as a Predictor of Analgesic Effect.

European journal of pain (London, England)·2026
Same author

Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Frontiers in cell and developmental biology·2026
Same journal

Epcoritamab Step-Up Dosing Regimen Selection and Optimization Using Repeated Time-to-Event Modeling for Cytokine Release Syndrome Risk Mitigation.

Clinical pharmacology and therapeutics·2026
Same journal

From Executor to Orchestrator: The Pharmacology Scientist in the Age of Agentic AI.

Clinical pharmacology and therapeutics·2026
Same journal

The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient.

Clinical pharmacology and therapeutics·2026
Same journal

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

Clinical pharmacology and therapeutics·2026
Same journal

Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

Clinical pharmacology and therapeutics·2026
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Feb 23, 2026

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
07:48

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Published on: May 16, 2016

12.2K

Inflammation: Treatment Progress and Limitations.

Ingolf Cascorbi1

  • 1Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.

Clinical Pharmacology and Therapeutics
|September 13, 2017
PubMed
Summary
This summary is machine-generated.

Understanding the genetic basis of chronic inflammatory diseases like IBD is improving. Identifying key inflammatory triggers has led to advanced therapies with better patient outcomes.

More Related Videos

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K

Related Experiment Videos

Last Updated: Feb 23, 2026

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
07:48

Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation

Published on: May 16, 2016

12.2K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

7.0K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Chronic immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD), psoriasis, and rheumatoid arthritis, are increasingly understood.
  • Genetic studies, particularly in IBD, have identified genes in innate mucosal defense and immune tolerance (e.g., NOD2).
  • Common genetic susceptibility loci suggest overlapping immune pathways in these conditions, though single genetic traits lack causality.

Discussion:

  • Elucidation of key inflammatory triggers such as tumor necrosis factor alpha (TNFα), integrins, and cytokines (IL-6, IL-23) has been crucial.
  • These discoveries have paved the way for novel pharmacological interventions.
  • Therapeutic outcomes for patients with these diseases have significantly improved.

Key Insights:

  • Genetic research has uncovered key pathways involved in immune-mediated diseases.
  • Identification of specific molecular targets has revolutionized treatment strategies.
  • Advances in understanding disease etiology directly translate to improved clinical results.

Outlook:

  • Continued genetic research will further refine our understanding of disease mechanisms.
  • Development of targeted therapies based on identified pathways holds promise for future treatments.
  • Personalized medicine approaches may emerge from deeper insights into genetic susceptibility and inflammatory triggers.